Dr. Seder received his BA degree from Johns Hopkins University, his MD degree from Tufts University, and his residency in Internal Medicine at New York Hospital-Cornell Medical Center. Dr. Seder came to the NIH in 1989 and performed postdoctoral training in the Laboratory of Immunology at the National Institute for Allergy and Infectious Diseases (NIAID) under Dr. William Paul. Dr. Seder was subsequently appointed as Chief of the Cellular Immunology Section in the Vaccine Research Center in the NIAID in 2000.
At the Vaccine Research Center, Dr. Seder has focused on the cellular and molecular mechanisms by which vaccines and adjuvants mediate protective immunity in mouse, and non-human primate (NHP) models of HIV, Malaria, Tuberculosis and cancer. Dr. Seder’s scientific focus has been on T cell quality, and how the route of vaccination can be used to generate protective tissue resident T cell immunity against TB and malaria. Recently, Dr. Seder has also focused his efforts on discovery of monoclonal antibodies to prevent malaria infection. Dr. Seder has translated his scientific discoveries and led the first in human clinical studies using intravenous vaccination to generate protective immunity with an attenuated malaria vaccine and using a monoclonal antibody to prevent malaria infection.
Over the past year, Dr. Seder has been intimately involved in COVID vaccine development with the Moderna mRNA vaccine in the non-human primate model of SARS-CoV2 infection. This work has focused on developing immune correlates and mechanisms of protection, durability of protection and how the vaccine will protect against viral variants.